AstraZeneca’s Forxiga Approved In China For Heart Failure

(RTTNews) – AstraZeneca Plc. (AZN.L, AZN) said Thursday that China has approved the company’s Forxiga or dapagliflozin to reduce the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure with reduced ejection fraction or HfrEF.Forxiga orRead MoreMarketsMarkets Feed